14-3-3η: Raising the Bar for
Early RA Diagnosis
Improved Clinical Outcomes:
Enabled by Early Diagnosis and
Augurex is a biotechnology company that is focused on developing biomarker blood tests that transform patient clinical management for better disease outcomes.
Biomarkers are substances in the body that inform patient conditions and assist with early diagnosis, optimization of treatment and disease monitoring. Extracellular 14-3-3η (eta) protein represents Augurex’s first commercialized blood test and also serves as a drug target for the personalized treatment of rheumatoid arthritis (RA). A novel 14-3-3η-centric autoimmune portfolio has emerged from this transformational biomarker, forming the basis of Augurex pipeline research. The key to our success is based on collaborations with international opinion-leading scientists to advance our research programs and commercialization relationships with innovative lab services companies who ensure that our products reach clinicians and patients who can benefit from them.
From the laboratory bench, through to clinical development and commercialization, the Augurex team has the core competencies to advance transformational biomarkers to the clinic.
Augurex develops biomarkers that transform patient clinical management for better disease outcomes.
Augurex’s autoimmune portfolio centers on the novelty that the 14-3-3η protein, which is normally inside of cells, is released into the extracellular space where it perpetuates disease processes.